2 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
Follow NF1 Mutation: new trials by email Literature Review of NF1 Mutation trials Research Report on NF1 Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway DCC-3084 - Advanced Solid Tumor, RAF Mutation | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 29 | 2024-05-14 | 2026-03-05 |
| Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. ABM-168 - Advanced Solid Tumor, RAS Mutation | Phase 1 | Terminated | ABM Therapeutics Corporation | 12 | 2023-03-30 | 2024-12-06 |
Melanoma (2) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Lung Neoplasms (1) · Pancreatic Neoplasms (1)
Lung Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Skin Diseases (2) · Skin Neoplasms (2) · Skin and Connective Tissue Diseases (2) · Thoracic Neoplasms (2)
ABM Therapeutics Corporation (1) · Deciphera Pharmaceuticals, LLC (1)
United States (2)